News 10 Mag 2024 BioVersys extends Series C financing round to 44.9 million Swiss francs BioVersys is bolstering its partnership with GSK in order to accelerate the development of alpibectir for the treatment of tuberculosis. GSK is s...
Aktuell 15 Mag 2024 Allegria Therapeutics nimmt 3,5 Millionen Dollar in Seed-Runde ein Allegria Therapeutics hat eine Seed-Finanzierung von 3,5 Millionen Dollar durch den Gründungsinvestor Forty51 Ventures erhalten. Das Biotech-Star...
News 31 Lug 2023 InSphero announces an award for 3D in vitro models InSphero, based in the canton of Zurich, and the Physicians Committee for Responsible Medicine have launched a joint award program. Five academic...
Aktuell 07 Mag 2024 UZH forscht an neuer Krebstherapie Forschende der Universität Zürich (UZH) entwickeln neue Krebstherapeutika. Die sogenannten Radiotheranostika sollen Tumore gleichzeitig lokalisie...
News 26 Mar 2024 Top Stories from Western Switzerland (March 2024) From innovative approaches in cardiac care and sustainable plastics to enhancing spinal cord injury therapies and advancing virtual power plants,...
News 05 Mar 2024 Immunocore turns to Oncobit platform The British biotechnology company Immunocore will in future make use of the platform developed by Oncobit, a medtech firm and spin-off from the U...
Aktuell 10 Mag 2024 BioVersys erweitert Serie-C-Runde auf 44,9 Millionen Franken BioVersys verstärkt die Zusammenarbeit mit GSK, um die Entwicklung von Alpibectir zur Behandlung von Tuberkulose zu beschleunigen. GSK beteiligt ...
News 14 Mar 2024 Bühler and Icos join forces to promote start-ups The Bühler Group and Icos Capital have agreed a partnership with the aim of networking start-ups active in the fields of chemicals and biotechnol...
Aktuell 31 Lug 2023 InSphero lobt Preis für 3D-In-vitro-Modelle aus InSphero und das Physicians Committee for Responsible Medicine starten gemeinsam ein Award-Programm. Dabei werden fünf akademische Teams mit 3D-M...
Actualités 17 Apr 2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
Événements S-GE Country Event: Opportunités de business en Inde 22 Mag 2024 16:15–18:20 Lugano Svizzera
Novità 02 Giu 2023 Le ultime ricerche indicano che il 20% delle aziende biotecnologiche europee ha attualmente sede in Svizzera Press release Una nuova ricerca condotta da IQVIA e pubblicata recentemente nello Swiss Biotech Report 2023 mostra che il 20% delle aziende biotecnologiche eur...
Factsheet 10 Apr 2024 Opportunità nell’importazione di alimenti trasformati in Indonesia Il mercato degli alimenti trasformati importati in Indonesia vale circa 19,4 miliardi di dollari. Il Paese offre crescenti opportunità commercial...
Evento S-GE Evento Paese India – Le opportunità per le PMI elvetiche 22 Mag 2024 16:15–18:20 Lugano Svizzera